InterCure (INCR.TA) Stock Price
InterCure Price
Over the last 19 years InterCure grew revenue by 14.3% annually, reaching 238.85 M ILS. Earnings per share have declined at 24.6% per year over the last 10 years. For InterCure, the net margin of -28.4% is up versus -57.2% a few years ago. The consensus 12-month price target for InterCure is 7.14 ILS, about 57.0% below where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 192% above its 52-week low.
InterCure stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of InterCure over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how InterCure stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing InterCure's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | InterCure Price |
|---|---|
| 9/4/2026 | 16.62 ILS |
| 9/3/2026 | 16.22 ILS |
| 9/2/2026 | 16.80 ILS |
| 9/1/2026 | 17.13 ILS |
| 8/31/2026 | 17.94 ILS |
| 8/28/2026 | 17.60 ILS |
| 8/27/2026 | 17.11 ILS |
| 8/26/2026 | 17.69 ILS |
| 8/25/2026 | 17.20 ILS |
| 8/21/2026 | 6.56 ILS |
| 8/20/2026 | 6.45 ILS |
| 8/19/2026 | 7.15 ILS |
| 8/18/2026 | 7.08 ILS |
| 8/17/2026 | 7.12 ILS |
| 8/14/2026 | 7.25 ILS |
| 8/13/2026 | 7.23 ILS |
| 8/12/2026 | 7.27 ILS |
| 8/11/2026 | 7.12 ILS |
| 8/10/2026 | 7.31 ILS |
| 8/7/2026 | 7.40 ILS |
| 8/6/2026 | 7.12 ILS |
| 8/5/2026 | 7.32 ILS |
| 8/4/2026 | 7.59 ILS |
| 7/31/2026 | 7.87 ILS |
| 7/30/2026 | 7.05 ILS |
| 7/29/2026 | 6.92 ILS |
| 7/28/2026 | 7.12 ILS |
| 7/27/2026 | 7.28 ILS |
| 7/24/2026 | 7.46 ILS |
| 7/22/2026 | 7.29 ILS |
InterCure Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
InterCure Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM ILS |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM ILS |
| EBITM ILS |
| EBIT MARGIN% |
| NET INCOMEM ILS |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.00 | 8.00 | 8.00 | – | – | – | – | – | 8.00 | 65.00 | 219.00 | 388.00 | 355.00 | 238.00 | 404.00 | 574.00 |
| -15.38 | -27.27 | – | – | – | – | – | – | – | 712.50 | 236.92 | 77.17 | -8.51 | -32.96 | 69.75 | 42.08 |
| 72.73 | 75.00 | 75.00 | – | – | – | – | – | 12.50 | 46.15 | 43.38 | 40.72 | 30.42 | 14.71 | 14.71 | 14.71 |
| 8.00 | 6.00 | 6.00 | 3.00 | 35.00 | 35.00 | 35.00 | 35.00 | 1.00 | 30.00 | 95.00 | 158.00 | 108.00 | 35.00 | 59.41 | 84.41 |
| -1.00 | -2.00 | -2.00 | – | – | 1.00 | -4.00 | -10.00 | -3.00 | -39.00 | 39.00 | 63.00 | 31.00 | -49.00 | 52.00 | 93.00 |
| -9.09 | -25.00 | -25.00 | – | – | – | – | – | -37.50 | -60.00 | 17.81 | 16.24 | 8.73 | -20.59 | 12.87 | 16.20 |
| -6.00 | 44.00 | -6.00 | – | – | – | -5.00 | -12.00 | -5.00 | -37.00 | 4.00 | 44.00 | -61.00 | -67.00 | 27.00 | 78.00 |
| -53.85 | -833.33 | -113.64 | – | – | – | – | 140.00 | -58.33 | 640.00 | -110.81 | 1,000.00 | -238.64 | 9.84 | -140.30 | 188.89 |
| 45.87 | 2.68 | 5.77 | 45.87 | 45.87 | 12.90 | 16.78 | 17.96 | 23.30 | 26.15 | 46.92 | 45.35 | 45.57 | 45.87 | 45.87 | 45.87 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales InterCure generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue InterCure retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare InterCure's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares InterCure has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against InterCure's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
InterCure stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
InterCure Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
InterCure business model & stock analysis
InterCure SWOT Analysis
Strengths
InterCure Ltd has a strong market presence and brand recognition in the healthcare industry.
The company is backed by a highly skilled and experienced management team.
InterCure has a diverse product portfolio, catering to different segments of the healthcare market.
Weaknesses
InterCure faces stiff competition from other established players in the market.
The company's reliance on a few key suppliers puts it at risk of supply chain disruptions.
InterCure's geographic presence is limited to a few regions, hindering its global expansion opportunities.
Opportunities
InterCure can leverage advancements in technology to develop innovative healthcare solutions.
The growing demand for healthcare services presents an opportunity for InterCure to expand its customer base and market share.
Strategic partnerships and collaborations can help InterCure penetrate new markets and reach a wider audience.
Threats
InterCure faces regulatory uncertainties, which could impact its product development and commercialization processes.
Economic downturns and fluctuations in healthcare spending pose a threat to InterCure's financial performance.
Competitive pricing and cost pressures in the healthcare industry can affect InterCure's profitability.
InterCure Segments
InterCure Revenue by Segment
3 Years
Max
Details
InterCure Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
InterCure historical P/E ratio, EBIT multiple, and P/S ratio
InterCure annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
InterCure shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
InterCure stock splits
Current InterCure forecasts and price targets in September 2026
Analyst Price Targets 2026InterCure Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/15/2022 | 0.26ILS | - | 108.00 MILS | - | 2022 Q3 |
| 5/16/2022 | 0.18ILS | - | 92.57 MILS | - | 2022 Q1 |
| 4/6/2022 | 0.14ILS | - | 77.03 MILS | - | 2021 Q4 |
| 11/16/2021 | 0.15ILS | - | 59.25 MILS | - | 2021 Q3 |
| 8/16/2021 | 0.14ILS | - | 39.58 MILS | - | 2021 Q2 |
InterCure shareholder structure
| % | Name |
|---|---|
31.03403% | |
4.11229% | |
0.46327% | |
0.23738% | |
0.21207% | |
0.10661% |
InterCure Beneficial Ownership Filings (SEC 13D/G)
InterCure Executives and Management Board
10 members · avg. age 58 · 10 % women
Management
Mr. Alexander Rabinovitch (51)
Chief Executive Officer, Director · since 2018
Mr. Amos Cohen (42)
Chief Financial Officer
Mr. Rami Levy
Chief of Operation - Canndoc’s
Mr. Ori Mimon
Co-Chief Executive Officer of Cannolam Ltd
Adv. Asaf Ohyaon
Co-Chief Executive Officer of Cannolam Ltd
Board of Directors
Mr. Ehud Barak (81)
Chairman of the Board · since 2018
Mr. Alon Granot (61)
Director
Ms. Lennie Grinbaum Michelson (46)
External Director
Mr. Gideon Hirschfeld (56)
External Director
Mr. David Salton (72)
Independent Director
Frequently asked questions about InterCure
InterCure Ltd is a leading company in the healthcare sector. The business model of InterCure revolves around the development and commercialization of innovative medical solutions to improve patient outcomes. With a strong focus on research and development, InterCure aims to provide advanced therapeutic solutions in areas such as respiratory, cardiovascular, and sleep disorders. The company's commitment to excellence and cutting-edge technology enables it to meet the evolving healthcare needs of individuals worldwide. With a customer-centric approach and a dedication to improving quality of life, InterCure Ltd stands out as a prominent player in the healthcare industry.
InterCure Ltd is primarily active in the medical cannabis industry.
The main competitors of InterCure Ltd in the market include established companies such as GW Pharmaceuticals, Tilray Inc., and Canopy Growth Corporation. These companies also operate within the medical cannabis industry and compete with InterCure in terms of product development, market share, and innovation. InterCure aims to differentiate itself by offering unique medical cannabis products and focusing on research and development to provide enhanced solutions for patients. Despite facing competition from various industry players, InterCure Ltd continues to strive for growth and maintain its market position through strategic partnerships and constant advancements in the field.
InterCure Ltd, a leading Israeli medical cannabis company, was founded in 2011. With a focus on improving patients' quality of life, InterCure is dedicated to research, development, production, and distribution of medical cannabis products. The company operates under the brand name "Canndoc" and holds a distinctive presence in both domestic and international markets. With a commitment to excellence, InterCure continuously strives to enhance patient care through its state-of-the-art cultivation facilities, advanced research initiatives, and partnerships with renowned international experts. With a rich history of innovation and a commitment to improving global healthcare, InterCure Ltd has established itself as a prominent player in the medical cannabis industry.
InterCure Ltd has achieved several significant milestones since its establishment. The company successfully developed and launched the innovative RESPeRATE device, a non-drug, FDA-cleared solution for hypertension. Additionally, InterCure Ltd has expanded its global presence, establishing partnerships and distribution channels in various markets. The company continues to enhance its product portfolio, offering advanced technologies and solutions to address various medical conditions. InterCure Ltd has also experienced notable financial growth and recognition, attracting investments and receiving prestigious awards for its advancements in healthcare. Overall, the company's milestones highlight its commitment to revolutionizing medical treatments and improving patients' well-being.
InterCure Ltd is primarily present in Israel, the United States, Canada, and Germany.
InterCure Ltd represents a strong commitment to promoting wellness and improving quality of life. The company values include innovation, integrity, and excellence. InterCure focuses on developing and commercializing therapeutic solutions that address unmet medical needs, particularly in the fields of respiratory disease and wellness. The corporate philosophy of InterCure revolves around advancing healthcare through cutting-edge technologies and research. With a dedicated team, InterCure aims to revolutionize the way illnesses are managed and to provide accessible treatments for better health outcomes. interCure Ltd is driven by its mission to enhance well-being and empower individuals to live healthier, more fulfilling lives.
Analysts currently set an average price target of 7.14 ILS for the InterCure stock (median: 7.14 ILS), implying -57.0 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the InterCure stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect InterCure to generate revenue of 574.00 M ILS and earnings per share of 1.70 ILS.
Converted at the current exchange rate, the InterCure share trades at 4.75 EUR (16.62 ILS).
The InterCure share (INCR.TA) is listed on 2 stock exchanges, including: NASDAQ (INCR).
InterCure Ltd was founded in 2000 to offer innovative digital health solutions. The company is based in Israel and provides various products and services targeting telemedicine, chronic diseases, and lifestyle management. Telemedicine InterCure offers an award-winning telemedicine platform called "CardioCare". This platform allows doctors to diagnose, treat, and monitor patients with high blood pressure without them having to come to a clinic. The platform includes a wireless blood pressure monitor connected to the patient's "CardioCare" app. By using this technology, the doctor can monitor the patient's blood pressure in real time and adjust the medication accordingly. Chronic diseases InterCure also offers products for managing chronic diseases such as asthma, diabetes, and COPD. The "RespeRate" is a breathing training device designed for patients with respiratory diseases. The device helps regulate breathing rhythm and patterns to improve the quality of breath and reduce symptoms. Lifestyle management Another product offered by InterCure is "Relaxing Moments". This app includes audio and video content for stress management and relaxation. The app was developed in collaboration with leading relaxation and stress reduction experts and includes exercises for breathing, meditation, and mindfulness. InterCure has also partnered with the company "Glucovation" to develop a "Smart Patch" for diabetics. This patch continuously measures blood glucose levels and sends this data to an app on the patient's smartphone. Through these continuous measurements, the patient can adjust medication in real time. Overall, InterCure offers a wide range of products and services aimed at improving patients' health and well-being. By utilizing digital technology, telemedicine, and collaborating with experts in various fields, InterCure supports patients in managing chronic diseases, relaxation, and disease prevention.
The expected revenue of InterCure is 574.00 M ILS. This figure is based on current financial data and reflects the company's business performance.
The expected profit of InterCure is 78.13 M ILS. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of InterCure is currently 9.76. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the InterCure stock.
The price-to-sales ratio (P/S) of InterCure is currently 1.33. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the InterCure stock.
The Eulerpool Quality Score for InterCure is 1/10.
The ISIN of InterCure is IL0011063760. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of InterCure is A1CZA8. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of InterCure is INCR.TA. The ticker symbol is used to trade InterCure shares on the stock exchange.
InterCure paid dividends every year for the past 0 years.
InterCure is assigned to the 'Health' sector.
The dividends of InterCure are distributed in ILS.
InterCure stock
InterCure Peer Group
InterCure Ticker
InterCure FIGI
All fundamentals and in-depth analysis of InterCure
Our stock analysis for InterCure stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of InterCure. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.